Drug Approval | December 28, 2021
India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod
It plans to deliver over 300 million doses to the Indian government
It plans to deliver over 300 million doses to the Indian government
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
Subscribe To Our Newsletter & Stay Updated
